Evidence map›Paper›PMID 38736639›Full record

ArticleKidney medicine2024

Pretransplant Treatment to Avoid Recurrent Membranous Nephropathy in a Kidney Transplant Recipient: A Case Report.

Erik L Lum, Jonathan E Zuckerman, Lama Abdelnour, Jennifer Terenzini, Gurbir Singh, Suphamai Bunnapradist

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Erik L LumDivision of Nephrology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
Jonathan E ZuckermanDepartment of Pathology and Laboratory Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
Lama AbdelnourDivision of Nephrology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
Jennifer TerenziniDepartment of Transplant Services, Kidney and Pancreas Transplant, UCLA, Los Angeles, California.
Gurbir SinghDivision of Nephrology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.
Suphamai BunnapradistDivision of Nephrology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles, California.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney transplant candidates with high anti-M-type phospholipase A2 receptor antibody activity may be at increased risk for early postkidney transplant recurrence and allograft loss. Pretransplant treatment to induce serological remission may be warranted to improve allograft survival. In this case report, a patient seeking their third kidney transplant, who lost 2 prior living donor transplants from early recurrent membranous nephropathy, underwent pretransplant treatment for membranous nephropathy with serological remission and no evidence of recurrent disease.

Indexed as

Kidney transplantmembranous nephropathyrecurrent glomerulonephritis

Identifiers

PMID38736639
PMCPMC11078694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.